Background Human papillomavirus (HPV) vaccination programmes were first implemented
in several countries worldwide in 2007. We did a systematic review and meta-analysis to …

Background More than 10 years have elapsed since human papillomavirus (HPV)
vaccination was implemented. We did a systematic review and meta-analysis of the …

Background Modelling studies have been widely used to inform human papillomavirus
(HPV) vaccination policy decisions; however, many models exist and it is not known whether …

Background Uptake of human papillomavirus (HPV) vaccine remains low in many countries,
although the bivalent and quadrivalent HPV vaccines given as a three‐dose schedule are …

Background Human papillomavirus (HPV) vaccination of girls with very high (> 90%)
coverage has the potential to eradicate oncogenic HPVs, but such high coverage is hard to …

Since 2006, 115 countries and territories have introduced human papillomavirus (HPV)
vaccination programs. Several efforts have been undertaken to evaluate the impact of HPV …

AIM: Clinical trials have shown prophylactic human papillomavirus (HPV) vaccines to be
effective against infection and disease. We examined whether HPV vaccination has the …

Background Human papillomavirus (HPV) vaccines were first licensed as a three-dose
series. Two doses are now widely recommended in some age groups; there are data …

Background After the introduction of a quadrivalent human papillomavirus (HPV) vaccination
programme in Australia in April, 2007, we measured the prevalence of vaccine-targeted and …

Abstract (See the editorial commentary by Castle and Zhao, on pages 335–7.) Our aim was
to examine the potential incremental impact of vaccinating boys against human …